To include your compound in the COVID-19 Resource Center, submit it here.

Kura gains on Phase II SCCHN data for tipifarnib

Kura Oncology Inc. (NASDAQ:KURA) jumped $4.95 (72%) to $11.80 on Friday after reporting late Thursday that tipifarnib met the primary

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE